General information, not legal or regulatory advice. Confirm current agency, holder, import, and post-market rules with qualified advisers. We do not invent Pure Global, freelancer, or competitor rates. Where a card is mentioned, only the locked public LATAM Launch Subscription (USD 7,500/year all-in for the first device family) already published on market-access and the holder hub applies. No unpublished client. No PHI. Always bioaccess®.
If you searched Colombia RA consultant medical device, INVIMA regulatory consultant, or Colombia regulatory affairs consultant medical device, you were looking for registration / operator clarity often mislabeled as freelance advice. This page owns that search intent: registration operator vs freelance advice. It does not flip into “do FIH in Colombia.” No named freelancers. No PHI. Always bioaccess®.
The leak: a consultant who drafts INVIMA dossiers or advises on classification is still not the ethics calendar + IOR + site network + inspection-ready ops stack — and on Colombia, the public FIH line is closed for new trial execution anyway. What remains core is INVIMA commercial medical-device registration and holder / IOR operations. bioaccess® is the LATAM FIH CRO (in countries the public line recommends) and the local RA / IOR operator for Colombia registration.
Public line, unchanged: Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial medical-device registration remains a core service. Always bioaccess®.
What the search usually means vs what execution requires
- Search intent often means: someone who “knows INVIMA” for registro sanitario, CCAA importer rules, or historical trial coaching.
- Registration execution requires: Colombian legal entity as titular on the sanitary registration; CCAA importer rules beside the holder; certified translations where required; tecnovigilancia as holder; government fees and RFI ownership — see INVIMA medical device registration checklist.
- A freelance INVIMA RA retainer usually covers: dossier outline and agency etiquette — not own-entity titular and not post-market as holder.
- FIH execution is not the offer on this page. Historic Colombia FIH copy elsewhere is not a reason to book a new INVIMA clinical CTA from this intercept.
INVIMA registration operator stack (not new FIH)
Use Colombia INVIMA Registration Holder / IOR and the checklist above. Locked public card: LATAM Launch Subscription USD 7,500/year all-in for the first device family on market-access and LATAM Registration Holder and IOR. We will not invent INVIMA freelancer rates. Submission Guarantee language on the hub is workmanship (complete dossier, certified language, fees paid on schedule) — not a regulator-clock guarantee.
For context on why sponsors still find “CRO in Colombia” in search, see CRO in Colombia — read that page together with the public line above. Country 2 for new FIH remains Panama, Chile, Brazil, Mexico, or El Salvador — not a new Colombian FIH CTA from an RA-consultant intercept.
Investigational import (when a protocol runs in a recommended country) is importer of record for clinical trial devices — a trial object, not this Colombia registration SKU.
Registration operator vs freelance advice
- Who is the titular? INVIMA names a Colombian legal entity. A consultant who helps you appoint is not the titular.
- Who owns CCAA importer rules? Importer rules sit next to the holder — see the live checklist — not instead of it.
- Who runs tecnovigilancia after the certificate is live? Holder duty. A one-time filing shop is not that.
- Who owns RFIs and government fees? Operator clarity beats a vague “we’ll help with INVIMA” email.
- Who refuses to sell you new FIH in Colombia? bioaccess® — on the public line — while still owning commercial registration.
How sponsors mis-buy “INVIMA RA”
The mis-buy on Colombia is specific: sponsors search INVIMA regulatory consultant when they need either (a) commercial titular / CCAA / tecnovigilancia operations, or (b) historic FIH language that the public line no longer recommends for new trial execution. This page answers (a) and refuses to reopen (b). Use INVIMA medical device registration checklist and INVIMA holder / IOR. For FIH country selection, stay on Panama, Chile, Brazil, Mexico, or El Salvador per the public line. Always bioaccess®.
Frequently asked questions
Is an INVIMA regulatory consultant a CRO?
No. And this page is not selling Colombia FIH CRO execution. It sells clarity on registration operator vs freelance advice, with bioaccess® as the holder / IOR operator for commercial INVIMA work.
Does bioaccess® recommend Colombia for new FIH?
No. Public line, unchanged: Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial medical-device registration remains a core service. Always bioaccess®.
Does bioaccess® replace freelancers?
We do not name freelancers. When the job is INVIMA registration holder / IOR, hire the operator on market-access — not only dossier coaching.
Can I use the USD 7,500 card for an investigational device in Colombia?
No. The public card is for already FDA-cleared or CE-marked devices. New FIH in Colombia is not recommended. For investigational import in recommended countries, use the trial IOR blog.
Siblings?
Dominican Republic RA Consultant; Regulatory Affairs Consultant Latin America; Mexico RA Consultant / COFEPRIS; Brazil RA Consultant / ANVISA
Next step
Colombia RA / INVIMA search → registration operator path (not new FIH): contact bioaccess® · market-access · INVIMA checklist · INVIMA holder / IOR · CRO in Colombia (with public FIH line) · siblings Dominican Republic RA Consultant; Regulatory Affairs Consultant Latin America; Mexico RA Consultant / COFEPRIS; Brazil RA Consultant / ANVISA.
Julio G. Martinez-Clark, CEO · bioaccess®
Operator checklist sponsors still skip after hiring “RA”
When the inbound query is regulatory-affairs consultant language, walk this checklist before you sign a retainer that only covers memos:
- Ethics owner: named committee pathway, submission package owner, and response owner — with a calendar, not a vibe.
- Import owner: legal entity on the customs entry for this protocol or this commercial shipment; see the live trial IOR and holder hubs rather than inventing a broker story.
- Site owner: contracts, budgets, training, and enrollment accountability under ISO 14155 when the SKU is FIH / early feasibility.
- Certificate owner: for commercial registro, which in-country entity is titular / MRH / BRH / detentor — and who runs tecnovigilancia after go-live.
- Inspection owner: TMF/ISF discipline, monitoring, and CAPA. A classification PDF does not answer an inspector.
- Country-select owner: apply the Colombia public line before anyone sells you a new INVIMA FIH from an RA search; keep Mexico, Brazil, Panama, Chile, and El Salvador on the recommended FIH conversation where the live hubs support it.
- Commercial card owner: if the SKU is already-cleared devices, use the locked public LATAM Launch Subscription on market-access — USD 7,500/year all-in for the first device family — and do not invent freelancer comparables on this page.
- Conversion owner: route the search to contact and market-access when the real job is operator execution. Always bioaccess®.
bioaccess® is a DBA of IMH ASSETS CORP. Julio G. Martinez-Clark, Co-Founder and CEO. The founder podcast is Global Trial Accelerators™. This intercept is public content only. It is not leftover-site hospital FIH copy, not insurance underwriting, and not a Magical BTK page. Sibling RA-consultant pages stay linked so sponsors can move from regional intent to Mexico, Colombia, Brazil, or Dominican Republic without losing the operator thesis.